Individualized treatment of genotype 1 naive patients: an Italian multicenter field practice experience.

ABSTRACT:

Background

Triple therapy including Telaprevir or Boceprevir still represents in many European countries the standard of care for patients with Hepatitis C Virus genotype 1 infection. The number of patients who received this treatment resulted generally lower than expected. We investigated, among naïve patients, number and characteristics of treatment candidates who were started on triple or dual therapy in comparison to those who were deferred.

Patients and methods

621 naïve treatment candidates were prospectively evaluated at each center. Factors associated with decision to defer or treat with dual or triple therapy were investigated by univariate and multivariate analyses. Rates of Sustained Virological Response and safety profile were analysed.

Results

Of candidat

SUBMITTER: Mangia A 

PROVIDER: S-EPMC4207756 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature